Brokerages Set HilleVax, Inc. (NASDAQ:HLVX) Target Price at $9.20

Shares of HilleVax, Inc. (NASDAQ:HLVX) have earned a consensus rating of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating. The average 1-year price target among brokerages that have covered the stock in the last year is $9.20.

Several equities research analysts have recently weighed in on the stock. Leerink Partners downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th. Guggenheim downgraded shares of HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $5.00 target price (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. HC Wainwright reissued a “neutral” rating and set a $2.00 target price on shares of HilleVax in a research report on Monday, August 12th. Finally, Leerink Partnrs downgraded shares of HilleVax from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 9th.

HilleVax Price Performance

Shares of NASDAQ HLVX opened at $1.82 on Friday. The firm has a fifty day moving average price of $1.82 and a 200-day moving average price of $7.18. The stock has a market cap of $90.49 million, a PE ratio of -0.55 and a beta of 0.80. HilleVax has a 1 year low of $1.55 and a 1 year high of $20.22.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). On average, research analysts expect that HilleVax will post -2.47 EPS for the current year.

Institutional Investors Weigh In On HilleVax

Several institutional investors and hedge funds have recently added to or reduced their stakes in HLVX. EntryPoint Capital LLC acquired a new position in shares of HilleVax during the 1st quarter valued at about $80,000. Tidal Investments LLC acquired a new position in HilleVax in the first quarter valued at about $207,000. Maven Securities LTD acquired a new position in HilleVax in the second quarter valued at about $217,000. Algert Global LLC purchased a new stake in HilleVax during the second quarter worth about $519,000. Finally, Rhumbline Advisers increased its stake in HilleVax by 27.0% during the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock worth $617,000 after purchasing an additional 9,073 shares during the period. Hedge funds and other institutional investors own 86.42% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.